Cediranib + Cediranib + Lomustine Chemotherapy + Placebo Cediranib
Phase 3Completed 0 views this week 0 watching⚡ Active
Interest: 40/100
40
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Recurrent Glioblastoma
Conditions
Recurrent Glioblastoma
Trial Timeline
Oct 1, 2008 → Sep 1, 2016
NCT ID
NCT00777153About Cediranib + Cediranib + Lomustine Chemotherapy + Placebo Cediranib
Cediranib + Cediranib + Lomustine Chemotherapy + Placebo Cediranib is a phase 3 stage product being developed by AstraZeneca for Recurrent Glioblastoma. The current trial status is completed. This product is registered under clinical trial identifier NCT00777153. Target conditions include Recurrent Glioblastoma.
What happened to similar drugs?
4 of 20 similar drugs in Recurrent Glioblastoma were approved
Approved (4) Terminated (0) Active (16)
🔄Nivolumab + Gemcitabine + Cisplatin + Carboplatin + Paclitaxel + PemetrexedOno PharmaceuticalPhase 3
Hype Score Breakdown
Clinical
17
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00777153 | Phase 3 | Completed |
Competing Products
20 competing products in Recurrent Glioblastoma